Lung Cancer
Conditions
Keywords
lung cancer, radiotherapy
Brief summary
Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
Detailed description
This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.
Interventions
None listed
Sponsors
China-Japan Friendship Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years old; 2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy; 3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy); 4. The target lesion of the lung receiving radiotherapy can be measured; 5. Imaging data can be obtained before and after radiotherapy; 6. Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.
Exclusion criteria
： 1. Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment; 2. The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy)； 3. Required imaging data cannot be obtained; 4. Other conditions considered by the investigator to be inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor regression rate | Within 1 year after completion of radiotherapy. | (1- post-treatment tumor volume/baseline tumor volume)×100% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | Within 1 year after completion of radiotherapy. | It refers to the proportion of patients who experience a complete or partial remission of tumors in response to treatment, as determined by RECIST criterion. |
| Disease control rate | Within 1 year after completion of radiotherapy. | It refers to the proportion of patients who experience an objective response (complete or partial remission) or stable disease in response to treatment, as determined by RECIST criterion. |
| Progression-free survival | From the start of treatment until the time of disease progression or death, assessed up to 120 months. | It's calculated from the start of treatment until the time of disease progression or the patient's death, whichever comes first. |
| Overall survival | From the start of treatment until the time of death, assessed up to 120 months. | It measures the length of time from the start of treatment until the death of the patient from any cause. |
| Adverse event rate | Within 1 year after completion of radiotherapy. | It refers to the frequency of treatment related adverse event. |
Countries
China
Contacts
Primary ContactGuangying Zhu, M.D.
Outcome results
None listed